Welcome to our dedicated page for Koninklijke Phil news (Ticker: PHG), a resource for investors and traders seeking the latest updates and insights on Koninklijke Phil stock.
Koninklijke Philips N.V. reports health technology developments across Diagnosis & Treatment, Connected Care and Personal Health. News from Royal Philips commonly covers order intake and comparable sales trends; product launches and regulatory clearances for imaging, image-guided therapy and AI software; and governance actions from its Annual General Meeting. Recent product themes include CT platforms such as Rembra and Spectral CT Verida, interventional guidance tools such as DeviceGuide and IntraSight Plus, and the Bridge Plus Occlusion Balloon for lead extraction procedures.
The company’s updates also address hospital monitoring, informatics, ultrasound, oral health and personal-care lines. Coverage reflects Philips’ role as a Netherlands-based global health technology company with securities traded on NYSE under PHG and on Euronext Amsterdam under PHIA.
Philips (NYSE: PHG) has received FDA 510(k) clearance for its latest UroNav version, advancing image-guided navigation technology for prostate cancer care. The system features a new advanced annotation workflow that enhances focal therapy procedures through improved precision in minimally invasive care.
The technology combines pre-procedural MRI imaging with real-time ultrasound for enhanced therapeutic precision. Clinical data shows a 30% improvement in high-risk prostate cancer diagnosis using fusion biopsy compared to standard methods. The system integrates with Philips DynaCAD Urology, streamlining focal therapy planning and delivery while expanding access to minimally invasive treatment options.
Philips (NYSE:PHG) and March of Dimes released a comprehensive study revealing a significant support gap for new mothers. The research shows that while 90% of people are willing to help new parents, 62% of mothers struggle to express their support needs, with this figure rising to 76% among Hispanic moms.
Key findings highlight that 2 out of 3 parents need the most support in the first three months postpartum, with 17% of mothers receiving no support outside their spouse. Mental health and self-care emerged as top priorities, with 93% of mothers considering self-care essential, yet 80% get less than an hour of personal time daily. The study also revealed that only 31% of the public are very familiar with postpartum health issues.
Philips (NYSE: PHG) has launched the ECG AI Marketplace, a centralized platform enabling cardiac care teams to access multiple AI-powered diagnostic tools from different vendors. Anumana becomes the first partner, integrating its FDA-cleared ECG-AI™ LEF algorithm for detecting low ejection fraction, an early indicator of heart failure.
The marketplace streamlines workflow integration and vendor management for U.S. hospitals and health systems using Philips' infrastructure. Anumana's algorithm, validated through studies involving over 150,000 patients and supported by nearly 100 peer-reviewed publications, will be available across Philips' ECG portfolio, including IntelliSpace ECG and Philips cardiographs.
Philips (NYSE: PHG) has partnered with Methodist Hospitals to implement advanced image-guided therapy (IGT) solutions across their Northlake and Southlake campuses. The strategic investment includes four new interventional labs featuring Philips Azurion systems, designed for neurovascular, cardiology, and complex interventional radiology procedures.
The implementation includes one Azurion biplane system for stroke intervention, two single plane labs for cardiovascular care, and a multi-purpose lab for complex procedures. The Azurion system has demonstrated a 17% reduction in procedure time, enabling treatment of an additional patient daily. Methodist Hospitals, with over 500 inpatient beds and 400 medical professionals, will utilize Philips' IntraSight with SyncVision technology for enhanced imaging and interventional capabilities.
Philips (NYSE: PHG) has announced a collaboration with March of Dimes to enhance maternal health education through the Philips Avent Pregnancy+ app. The partnership will integrate March of Dimes content into the app, focusing on critical topics such as NICU preparation, preterm birth, and vaccinations. The Pregnancy+ app, with over 80 million lifetime downloads, offers comprehensive pregnancy guidance including 800+ articles, 3D baby models, and expert-led courses.
The collaboration will emphasize the Low Dose, Big Benefits Campaign, promoting low dose aspirin for preventing pregnancy-related hypertensive disorders. Additionally, both organizations will conduct research using aggregated app data and surveys to gather insights for improving maternal and baby health outcomes.
[ "Partnership with leading nonprofit March of Dimes enhances Philips' maternal health education offering", "Pregnancy+ app has significant market presence with over 80 million lifetime downloads", "Collaboration enables data collection and research opportunities through app analytics and surveys", "Expansion of educational content addressing critical maternal health issues" ]Philips (NYSE: PHG) has launched the RADIQAL (Radiation Dose and Image Quality Trial) study to evaluate its new ultra-low X-ray dose technology for coronary procedures. The multicenter trial will enroll 824 patients across 6 hospitals in Spain, Czech Republic, Denmark, and the US, with the first patient enrolled at Aarhus University Hospital, Denmark.
The study aims to compare radiation exposure, image quality, and procedural performance between Philips' new ultra-low dose technology and existing ClarityIQ technology, both integrated into the Azurion image-guided therapy system. The new technology features an ultra-low dose protocol that reduces X-ray exposure by 50% compared to the lowest setting currently available on Azurion systems with ClarityIQ. The technology has received CE marking but is not yet FDA-cleared.